Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences Inc.

The latest update is out from Pharmacorp Rx Inc. ( ($TSE:PCRX) ). PharmaCorp Rx Inc. announced the approval from the TSX Venture Exchange for the s...

PharmaCorp Rx Inc. Secures TSX Venture Approval for Warrant Listing

An announcement from Pharmacorp Rx Inc. ( ($TSE:PCRX) ) is now available. PharmaCorp Rx Inc. has successfully closed a C$23 million bought deal pub...

PharmaCorp Closes C$23 Million Public Offering to Fuel Expansion

Pharmacorp Rx Inc. ( ($TSE:PCRX) ) just unveiled an announcement. PharmaCorp Rx Inc. has announced a C$15 million bought deal public offering, invo...

PharmaCorp Rx Inc. Announces C$15 Million Public Offering to Fuel Expansion

Pacira (($PCRX)) announced an update on their ongoing clinical study. Pacira Pharmaceuticals is conducting a study titled ‘A Multicenter, Open-labe...

Current Quarter	$0.64	Next Quarter	$0.48
Current Year	$2	Next Year	$2.3
QoQ Growth	-25.0%	YoY Growth	+15.0%
3Y EPS CAGR	-62.2%	Target Price	$28.60
Consensus	Buy	Upside	+24.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PCRX	$23.05	+1.10%	740.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PCRX	$23.05	+1.1%	740.58K
3
4
5
6

PCRX

PCRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Pacira BioSciences Inc. Data in Excel

Get Pacira BioSciences Inc. Data in Excel